Capital International Sarl Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital International Sarl raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 186,920 shares of the company’s stock after buying an additional 16,397 shares during the quarter. Capital International Sarl owned approximately 0.22% of CRISPR Therapeutics worth $7,357,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Magnetar Financial LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter worth approximately $359,000. Capital Market Strategies LLC purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $461,000. Vanguard Group Inc. grew its stake in shares of CRISPR Therapeutics by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock valued at $68,329,000 after buying an additional 10,579 shares during the period. KBC Group NV increased its holdings in shares of CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after buying an additional 57,696 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth $3,231,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In other news, Director John Greene purchased 7,000 shares of the company’s stock in a transaction on Wednesday, February 26th. The shares were bought at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares of the company’s stock, valued at $313,950. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $37.77 on Friday. The stock has a market capitalization of $3.24 billion, a PE ratio of -8.64 and a beta of 1.85. The business’s fifty day moving average price is $40.93 and its 200 day moving average price is $43.76. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CRSP shares. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target for the company in a research report on Wednesday, February 12th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Friday, March 21st. Chardan Capital cut their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Finally, The Goldman Sachs Group cut their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.